Capricor Therapeutics, Inc. $CAPR Shares Bought by HBK Sorce Advisory LLC

HBK Sorce Advisory LLC raised its stake in Capricor Therapeutics, Inc. (NASDAQ:CAPR) by 19.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 203,705 shares of the biotechnology company’s stock after acquiring an additional 33,128 shares during the quarter. HBK Sorce Advisory LLC owned approximately 0.45% of Capricor Therapeutics worth $5,879,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. ProShare Advisors LLC acquired a new position in Capricor Therapeutics in the fourth quarter valued at approximately $203,000. Allworth Financial LP lifted its holdings in Capricor Therapeutics by 5,021.5% in the fourth quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 3,264 shares during the period. Moody Aldrich Partners LLC acquired a new position in Capricor Therapeutics in the fourth quarter valued at approximately $6,025,000. UBS Group AG lifted its holdings in Capricor Therapeutics by 91.0% in the fourth quarter. UBS Group AG now owns 238,216 shares of the biotechnology company’s stock valued at $6,875,000 after acquiring an additional 113,499 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in Capricor Therapeutics by 16.1% in the fourth quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock valued at $73,936,000 after acquiring an additional 355,161 shares during the period. 21.68% of the stock is owned by institutional investors and hedge funds.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock opened at $28.87 on Monday. The stock has a market capitalization of $1.67 billion, a PE ratio of -12.44 and a beta of 0.48. Capricor Therapeutics, Inc. has a 12 month low of $4.30 and a 12 month high of $40.37. The business has a 50 day simple moving average of $31.68 and a 200-day simple moving average of $25.14.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.04). On average, equities research analysts anticipate that Capricor Therapeutics, Inc. will post -0.75 EPS for the current fiscal year.

Insider Activity at Capricor Therapeutics

In related news, CFO Anthony Bergmann sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $31.70, for a total transaction of $792,500.00. Following the completion of the sale, the chief financial officer directly owned 8,223 shares in the company, valued at approximately $260,669.10. The trade was a 75.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Karimah Es Sabar sold 7,529 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $32.00, for a total value of $240,928.00. Following the sale, the director owned 7,529 shares of the company’s stock, valued at $240,928. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 172,529 shares of company stock valued at $5,302,440 over the last quarter. 9.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on CAPR. B. Riley Financial boosted their price target on Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a report on Friday, March 13th. Cantor Fitzgerald set a $62.00 price target on Capricor Therapeutics and gave the company an “overweight” rating in a report on Friday, March 13th. Piper Sandler reissued an “overweight” rating and issued a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Capricor Therapeutics in a report on Wednesday, May 13th. Finally, Roth Mkm restated a “buy” rating and issued a $38.00 price objective on shares of Capricor Therapeutics in a research report on Friday, May 15th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Capricor Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $48.36.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.